Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Recombinant Hepatitis B Vaccine With Different Adjuvants in Healthy Adult Volunteers

NCT00697125 Phase 2 COMPLETED

The purpose of this study is to evaluate the immunogenicity and reactogenicity of various formulations of recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers following the 0, 1, 6 months schedule

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	COMPLETED
Enrolment	60
Start date	1993-06
Completion	1994-07

Conditions

• Hepatitis B

Interventions

• Engerix™-B
• HBV-MPL vaccine (208129)
• Hepatitis B vaccine, experimental formulation

Primary outcomes

• Occurrence and intensity of solicited local and general symptoms — 8 days follow-up after vaccination

Countries

Belgium